arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Profound Medical Corp.

PROF

$7.41 ▼ -0.51 (-6.50%) at close

8 Visible periods

29 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Moderately Bearish

auto_awesome

Analytical Summary

Profound Medical Corp. faces fundamental challenges with weakness in Return on Common Equity (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $224.0M

Dividend Yield —

Revenue Growth 50.7% ↗

Op. Margin -256.3% ↗

ROIC -58.5% ↘

FCF / Share $-1.27 ↘

Trailing P/E 5.3x

Price / Book 4.1x

FCF Yield —

Debt / Equity 0.07

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$16.10M

↑ +50.7% —

Net Income Profit after all expenses

$-42.57M

↓ -53.0% —

Operating Margin Operating profit as % of sales

-256.3%

↑ +17.2% 0th

FCF / Share Free cash flow per share

$-1.27

↓ -34.1% —

Long-Term Debt Long-term obligations

$4.50M

↓ -3.5% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↑

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 40-F ↗	FY 2021 Dec 31, 2021 40-F ↗	FY 2020 Dec 31, 2020 40-F ↗	FY 2019 Dec 31, 2019 40-F ↗	FY 2018 Jan 1, 2019 40-F ↗
Revenue Growth YoY (%)	50.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+534%)	48.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+504%)	—	—	—	—	—	—
EPS Growth YoY (%)	25.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-16.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-53.0% Weak ↓ Weak Declining Year-over-year change in net income	1.8% Caution ↑ Caution Improving Year-over-year change in net income	1.2% Caution ↑ Caution Improving Year-over-year change in net income	6.6% Fair ↑ Fair Improving Year-over-year change in net income	-42.0% Weak Weak Year-over-year change in net income	-42.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-34.1% Weak Weak Year-over-year change in free cash flow	11.3% Fair Fair Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 40-F ↗	FY 2021 Dec 31, 2021 40-F ↗	FY 2020 Dec 31, 2020 40-F ↗	FY 2019 Dec 31, 2019 40-F ↗	FY 2018 Jan 1, 2019 40-F ↗
Operating Margin (%) (%)	-256.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1808%)	-309.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2164%)	-398.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2753%)	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
Profit Margin (%) (%)	-264.4% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2304%)	-260.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2270%)	-393.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3379%)	—	—	—	—	—
FCF Margin (%) (%)	-238.4% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-219.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-314.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 40-F ↗	FY 2021 Dec 31, 2021 40-F ↗	FY 2020 Dec 31, 2020 40-F ↗	FY 2019 Dec 31, 2019 40-F ↗	FY 2018 Jan 1, 2019 40-F ↗
Return on Invested Capital (%)	-58.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-50.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-74.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—
Return on Capital (%) (%)	-53.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-65.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-64.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-527%)	-46.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-407%)	-90.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-705%)	—	—	—	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 40-F ↗	FY 2021 Dec 31, 2021 40-F ↗	FY 2020 Dec 31, 2020 40-F ↗	FY 2019 Dec 31, 2019 40-F ↗	FY 2018 Jan 1, 2019 40-F ↗
Debt to Equity (x)	0.07x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-89%)	0.08x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-87%)	0.23x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-62%)	—	—	—	—	—
Interest Coverage (x)	-104.71x Weak Weak Operating income divided by interest expense Optimal: > 5x	-55.10x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—
Net Debt (USD)	$-55.22M	$-50.25M	$-19.11M	—	—	—	—	—
Debt / EBITDA (x)	-0.11x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.14x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.25x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 40-F ↗	FY 2021 Dec 31, 2021 40-F ↗	FY 2020 Dec 31, 2020 40-F ↗	FY 2019 Dec 31, 2019 40-F ↗	FY 2018 Jan 1, 2019 40-F ↗
Revenue per Share (USD)	$0.53	$0.43	$0.34	—	—	—	—	—
Basic EPS, GAAP (USD)	$1.41	$1.12	$1.34	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.27	$-0.95	$-1.07	—	—	—	—	—
Book Value per Share (USD)	$1.83	$2.01	$1.46	—	—	—	—	—
Tangible Book Value per Share (USD)	$1.83	$2.01	$1.46	—	—	—	—	—
Basic Weighted Avg Shares (shares)	30.23M	24.77M	21.18M	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 40-F ↗	FY 2021 Dec 31, 2021 40-F ↗	FY 2020 Dec 31, 2020 40-F ↗	FY 2019 Dec 31, 2019 40-F ↗	FY 2018 Jan 1, 2019 40-F ↗
Working Capital (USD)	$70.01M	$62.50M	$35.53M	—	—	—	—	—
LT Debt (USD)	$4.50M	$4.66M	$7.10M	—	—	—	—	—
Total Equity (USD)	$66.43M	$60.42M	$31.22M	—	—	—	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 40-F ↗	FY 2021 Dec 31, 2021 40-F ↗	FY 2020 Dec 31, 2020 40-F ↗	FY 2019 Dec 31, 2019 40-F ↗	FY 2018 Jan 1, 2019 40-F ↗
Sales/Revenue/Turnover (USD)	$16.10M	$10.68M	$7.20M	—	—	—	—	—
Depreciation Expense (USD)	$373.00K	$707.00K	$727.00K	—	—	—	—	—
Net Income, GAAP (USD)	$-42.57M	$-27.82M	$-28.32M	$-28.67M	$-30.70M	$-21.62M	$-15.22M	—
Operating Cash Flow (USD)	$-38.21M	$-23.45M	$-22.61M	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 15 quarters

Profound Medical Corp.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PROF with peers